• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , Sept. 27

RANBAXY Laboratories Ltd has received approval from the US Food and Drug Administration (FDA) to manufacture and market Clarithromycin tablets 250 mg and 500 mg used for treating infections.

According to a company statement, the Office of Generic Drugs has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug — Abbott Laboratories' Biaxin tablets. The total market sales for Clarithromycin are around $554 million.

Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated micro-organisms in the throat, lungs and even skin.

"We are planning to commercialise Clarithromycin tablets after the expiration of US patent in May 2005," said Mr Jay Deshmukh, Vice-President of Intellectual Property, Ranbaxy Laboratories.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
MRPL to invest Rs 200 cr for Euro IV facilities

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line